Home>
Stocks>
Everest Organics Ltd

Everest Organics Ltd (524790)

₹136.25▲0.04%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Everest Organics Ltd share Performance

₹136.1
₹139.95
₹136.25
0.11%
Low
Day's Volatility:2.83%
High
2.72%
₹97.02
₹161.7
₹136.25
28.79%
Low
52 Weeks Volatility:47.47%
High
18.68%

Returns %
1 Month Return	+ 9.04 %
3 Month Return	+ 0.07 %
1 Year Return	+ 32.85 %

Market Stats
Previous Close	₹₹136.30
Open	₹₹136.80
Volume	₹2,519.00
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹109.04Cr

Company Information

Everest Organics was established in Hyderabad, India in February 1993 to produce bulk drugs and formulations. It held a public issue in January 1995 for the financing of its project. Commercial production of Ciprofloxacin and Omeprazole commenced in February 1996 and Everest Organics decided to increase the capacity of Ciprofloxacin from 30 tonnes a year to 120 tonnes a year and also to produce Enrofloxacin/Naproxen. The company have also expanded their installed capacity of Benzimidazole to 120 tonnes annually and the installed capacity of Omeprazole Op Sulphide was increased from 15 to 30 tonnes a year. By increasing their production capabilities, Everest Organics aims to be a major supplier of pharmaceuticals across India.

Share Price: ₹136.25 per share as on 17 May, 2024 04:01 PM
Market Capitalisation: ₹109.04Cr as of today
Listing date: 01 Jan, 0001
Chairperson Name: K. Ramakrishnam Raju

Organisation	Everest Organics Ltd
Headquarters	Hyderabad
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Fundamentals of Everest Organics Ltd

Insights on Everest Organics Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, Everest Organics stock has moved up by 9.6%
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 94.5% return, outperforming this stock by 61.6%
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 123.6% return, outperforming this stock by 183.2%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.15% of holdings in Mar 2024 quarter
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 25.82% to 25.79% in Mar 2024 quarter